title: Tracking Down Response and Resistance to TRK Inhibitors.
abstract: Two recent studies validate the LMNA-NTRK1 fusion as an oncogenic driver and therapeutic target of TRK inhibitors. The LMNA-NTRK1 fusion occurs at low frequency across multiple tumor types. The studies highlight the increasing need to develop molecular biomarker-based clinical trials across cancer subtypes.
authors.affiliation: Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, California. Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
authors.forename: Ross A
authors.initials: RA
authors.lastname: Okimoto
authors.affiliation: Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, California. Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California. trever.bivona@ucsf.edu.
authors.forename: Trever G
authors.initials: TG
authors.lastname: Bivona
mesh_terms: D001932:Brain Neoplasms / Q000378:metabolism* / Q000556:secondary; D018932:Chemokine CCL2 / Q000037:antagonists & inhibitors / Q000378:metabolism; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D006801:Humans; D009928:Organ Specificity; D051059:PTEN Phosphohydrolase / Q000172:deficiency*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D054852:Small Molecule Libraries / Q000494:pharmacology / Q000627:therapeutic use; D059016:Tumor Microenvironment
chemical_list: C111835:CCL2 protein, human; D018932:Chemokine CCL2; D047428:Protein Kinase Inhibitors; D054852:Small Molecule Libraries; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human